Methods and systems for screening using microcapillary arrays

The microcapillary array system allows for high-throughput screening and recovery of variant proteins by measuring specific affinity associations, addressing the issue of sample damage in existing methods and enabling efficient protein identification and characterization.

JP2024161355AInactive Publication Date: 2024-11-19XCELLA BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024111606
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-12-12
Filing Date
2024-07-11
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing high-throughput screening methods for biological samples, such as DNA microarrays, often fail to recover the biological sample without damaging it, limiting the ability to analyze and recover identified biomolecules.

Method used

A microcapillary array system comprising microcapillaries with variant proteins, immobilized target molecules, and reporter elements, allowing for specific affinity association measurement and subsequent isolation of microcapillaries of interest.

Benefits of technology

Enables high-throughput screening and recovery of variant proteins with minimal sample damage, facilitating the identification and characterization of proteins with desirable properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161355000001
    Figure 2024161355000001
  • Figure 2024161355000002
    Figure 2024161355000002
  • Figure 2024161355000003
    Figure 2024161355000003
Patent Text Reader

Abstract

To develop methods and systems for improved micro-scale screening and analysis having high-throughput capability, in particular, methods and systems allowing recovery of samples identified in the screening and analysis.SOLUTION: The methods utilize large-scale arrays of microcapillaries, where each microcapillary comprises a solution containing a variant protein, an immobilized target molecule, and a reporter element. Immobilized target molecules may include any molecule of interest, including proteins, nucleic acids, carbohydrates, and other biomolecules. The association of a variant protein with a molecular target is assessed by measuring a signal from the reporter element. The contents of microcapillaries identified in the assays as containing variant proteins of interest can be isolated, and cells expressing the variant proteins of interest can be characterized.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 433,210, filed December 12, 2016, all of which are expressly incorporated herein by reference in their entireties. [Background technology]

[0002] The analysis of biological samples, including the identification, characterization, and reengineering of proteins, nucleic acids, carbohydrates, and other important biomolecules, has benefited greatly from the expansion of sample numbers and the reduction of sample sizes. For example, two-dimensional microarrays of biological materials, such as DNA microarrays, have enabled the development of high-throughput screening methods that involve multiplexed approaches for processing samples and detecting results.

[0003] The above approaches have in some cases benefited from their combination with optical detection techniques to identify the analytes of interest using fluorescence or other corresponding specific and sensitive labeling approaches.

[0004] While such techniques provide analytical information about a particular sample, such as the presence and potential amount of a particular biomolecule in solution, or the sequence of a particular nucleic acid or polypeptide, they typically cannot recover the biological sample identified by the assay without inactivating or otherwise damaging the sample of interest.

[0005] Thus, there is a continuing need to develop improved microscale screening and analysis methods and systems with high throughput capabilities, particularly methods and systems that allow for the recovery of samples identified in screening and analysis. Summary of the Invention

[0006] The present disclosure addresses these and other needs by providing, in one aspect, a method for screening a population of mutant proteins comprising the steps of: providing a microcapillary array comprising a plurality of microcapillaries, each microcapillary comprising a mutant protein, an immobilized target molecule, and a reporter element, wherein the mutant protein associates with the immobilized target molecule with a particular affinity; and Measuring a signal from the at least one reporter element indicative of association of the at least one mutant protein with the at least one immobilized target molecule to identify the at least one microcapillary of interest.

[0007] In some embodiments, the method further comprises isolating the contents of the microcapillary of interest.

[0008] In another embodiment, a system for screening a population of mutant proteins is provided, comprising: An array comprising a plurality of microcapillaries, each microcapillary containing a mutant protein, an immobilized target molecule, and a reporter element, wherein the mutant protein associates with the immobilized target molecule with a particular affinity.

[0009] In some embodiments, the system further comprises a microscope.

[0010] In some embodiments, the system further comprises a light source and a detector.

[0011] In some embodiments, the system further comprises an extraction device.

[0012] In some embodiments, the system further comprises a two-stage sample collection element.

[0013] In some embodiments, the present invention provides a method of screening a population of mutant proteins comprising the steps of: providing a microcapillary array comprising a plurality of microcapillaries, each microcapillary comprising a mutant protein, an immobilized target molecule, and a reporter element, wherein the mutant protein associates with the immobilized target molecule with a particular affinity; and Measuring a signal from the at least one reporter element indicative of association of the at least one mutant protein with the at least one immobilized target molecule to identify the at least one microcapillary of interest.

[0014] In some embodiments, the mutant protein is expressed by an expression system.

[0015] In some embodiments, the expression system is a cell-free expression system.

[0016] In some embodiments, the expression system is a cellular expression system.

[0017] In some embodiments, the cellular expression system is animal-, fungal-, bacterial-, insect-, or plant-based.

[0018] In some embodiments, the cell expression system is a yeast system.

[0019] In some embodiments, the mutant protein is a soluble protein.

[0020] In some embodiments, the target molecule is a target protein or polypeptide, a target nucleic acid, a target carbohydrate, or a combination of each.

[0021] In some embodiments, the target molecule is immobilized on a surface.

[0022] In some embodiments, the surface is the surface of a cell.

[0023] In some embodiments, the target molecule is a naturally occurring protein.

[0024] In some embodiments, the surface is the surface of a bead.

[0025] In some embodiments, the surface is a surface of a microcapillary wall.

[0026] In some embodiments, the surface is a surface configured to settle into the microcapillary by gravitational settling.

[0027] In some embodiments, the reporter element is a labeled antibody or other binding molecule.

[0028] In some embodiments, the labeled antibody or other binding molecule is a fluorescently labeled antibody or other binding molecule.

[0029] In some embodiments, the labeled antibody is a primary antibody or a secondary antibody.

[0030] In some embodiments, the labeled antibody or other binding molecule is an enzyme-linked antibody or other binding molecule.

[0031] In some embodiments, the reporter element is activated within the cell and the target molecule is immobilized on the surface of the cell.

[0032] In some embodiments, the reporter element comprises green fluorescent protein or a mutant.

[0033] In some embodiments, the signal is a fluorescent signal, an absorbance signal, a bright field signal, or a dark field signal.

[0034] In some embodiments, each microcapillary in the microcapillary array contains between 0 and 5 mutant proteins from a population of mutant proteins.

[0035] In some embodiments, the microcapillary array comprises at least 100,000, at least 300,000, at least 1,000,000, at least 3,000,000, or at least 10,000,000 microcapillaries.

[0036] In some embodiments, each microcapillary further comprises an agent for improving the viability of the cell expression system.

[0037] In some embodiments, the agent is methylcellulose, dextran puronic F-68, polyethylene glycol, or polyvinyl alcohol.

[0038] In some embodiments, the agent is a growth medium.

[0039] In some embodiments, the signal is measured by an optical detector.

[0040] In some embodiments, the signal is measured by microscopy.

[0041] In some embodiments, the method further comprises isolating the contents of the microcapillary of interest.

[0042] In some embodiments, the contents of a microcapillary of interest are isolated by pulsing the microcapillary of interest with a laser.

[0043] In some embodiments, the laser is a diode-pumped Q-switched laser.

[0044] In some embodiments, a laser is directed at the water-glass interface between the microcapillary wall and the sample contained in the microcapillary.

[0045] In some embodiments, the contents of the microcapillary of interest are isolated using a two-stage sample collection element.

[0046] In some embodiments, the microcapillaries do not contain microparticles, magnetic microparticles, magnetic beads, or electromagnetic radiation absorbing materials capable of inhibiting the transmission of electromagnetic radiation.

[0047] The present invention also provides a system for screening a population of mutant proteins comprising: An array comprising a plurality of microcapillaries, each microcapillary containing a mutant protein, an immobilized target molecule, and a reporter element, wherein the mutant protein associates with the immobilized target molecule with a particular affinity.

[0048] In some embodiments, the mutant protein is expressed by an expression system.

[0049] In some embodiments, the expression system is a cell-free expression system.

[0050] In some embodiments, the expression system is a cellular expression system.

[0051] In some embodiments, the cellular expression system is animal-, fungal-, bacterial-, insect-, or plant-based.

[0052] In some embodiments, the cell expression system is a yeast system.

[0053] In some embodiments, the mutant protein is a soluble protein.

[0054] In some embodiments, the target molecule is a target protein or polypeptide, a target nucleic acid, a target carbohydrate, or a combination of each.

[0055] In some embodiments, the target molecule is immobilized on a surface.

[0056] In some embodiments, the surface is the surface of a cell.

[0057] In some embodiments, the target molecule is a naturally occurring protein.

[0058] In some embodiments, the surface is the surface of a bead.

[0059] In some embodiments, the surface is a surface of a microcapillary wall.

[0060] In some embodiments, the surface is a surface configured to settle into the microcapillary by gravitational settling.

[0061] In some embodiments, the reporter element is a labeled antibody or other binding molecule.

[0062] In some embodiments, the labeled antibody or other binding molecule is a fluorescently labeled antibody or other binding molecule.

[0063] In some embodiments, the labeled antibody is a primary antibody or a secondary antibody.

[0064] In some embodiments, the labeled antibody or other binding molecule is an enzyme-linked antibody or other binding molecule.

[0065] In some embodiments, the reporter element is activated within the cell and the target molecule is immobilized on the surface of the cell.

[0066] In some embodiments, the reporter element comprises green fluorescent protein or a mutant.

[0067] In some embodiments, the signal is a fluorescent signal, an absorbance signal, a bright field signal, or a dark field signal.

[0068] In some embodiments, each microcapillary in the microcapillary array contains between 0 and 5 mutant proteins from a population of mutant proteins.

[0069] In some embodiments, the microcapillary array comprises at least 100,000, at least 300,000, at least 1,000,000, at least 3,000,000, or at least 10,000,000 microcapillaries.

[0070] In some embodiments, each microcapillary further comprises an agent for improving the viability of the cell expression system.

[0071] In some embodiments, the agent is methylcellulose, dextran puronic F-68, polyethylene glycol, or polyvinyl alcohol.

[0072] In some embodiments, the agent is a growth medium.

[0073] In some embodiments, the system further comprises a light source and a detector.

[0074] In some embodiments, the system further comprises a microscope.

[0075] In some embodiments, the system further comprises an extraction device.

[0076] In some embodiments, the extraction device comprises a diode-pumped Q-switched laser.

[0077] In some embodiments, the system further comprises a two-stage sample collection element.

[0078] In some embodiments, the microcapillaries do not contain microparticles, magnetic microparticles, magnetic beads, or electromagnetic radiation absorbing materials capable of inhibiting the transmission of electromagnetic radiation. [Brief description of the drawings]

[0079] [Figure 1-A] Schematic diagram of the steps of an exemplary microcapillary screening assay. The left-hand view of each panel is a cross-sectional side view of a single microcapillary. The right-hand view of each panel is a bottom view of a small portion of a microcapillary array. The shading in each example is intended to indicate electromagnetic signals such as fluorescence. [Figure 1-B] Same as above. [Figure 1-C] Same as above. [Figure 2-A] Shown are bottom views of a small portion of a microcapillary array illustrating hybridoma screening for mammalian cells, where cells are imaged using either bright field (Figure 2A), LiveGreen (Figure 2B), or a fluorescent anti-mouse secondary antibody (Figure 2C). [Figure 2-B] Same as above. [Figure 2-C] Same as above. [Diagram 3] Shown are images of microcapillaries containing both A431 target cells and hybridoma cells over a 4 hour incubation period. [Figure 4-A] Shown are images of a small section of a microcapillary array highlighting expressing and non-expressing yeast cells versus mammalian cells, where cells are imaged using either bright field (Figure 4A) or fluorescent antibodies (Figure 4B). [Figure 4-B] Same as above. [Fig. 5-AB] 1 shows the growth of immortalized human cells in microcapillary arrays over a six day period. [Figure 5-C-D] Same as above. [Fig.5-EF] Same as above. [Figure 5-G] Same as above. [Figure 6-A] 1A-1D are different views of a microscope system designed to implement the screening method of the present disclosure. [Figure 6-B] Same as above. [Figure 6-C] Same as above. [Figure 6-D] Same as above. [Figure 6-E] Same as above. [Figure 7] Illustrated are exemplary embodiments of cellular (including mammalian or yeast) expression and binding to mammalian cells using the present invention. Each one of the four panels represents the microcavity of one microcapillary over time. [Figure 8-A] 8A) Each of the four panels represents a microcavity of one microcapillary over time. 8B) Potential readouts from an exemplary assay embodiment are provided. [Figure 8-B] Same as above. [Figure 9] 1 shows exemplary fluorescence and bright field data generated by the exemplary assay described in Example 6. [Figure 10] Illustrated are exemplary embodiments of cellular (including mammalian or yeast) expression and binding to immobilized targets on solid supports (such as beads) using the present invention. Each one of the four panels represents the microcavity of one microcapillary over time. [Figure 11] Shows an exemplary embodiment of cell (including mammalian or yeast) expression and functional reporter response using the present invention. Each of the four panels represents one microcavity of a microcapillary over time. Reporters can include any detectable reporter, including, for example, GFP, YFP, and / or RFP, as well as any fluorophore described herein or known in the art. [Figure 12-A] Examples of IgG1, IgG2, IgG3, and IgG4 sequences are provided. [Figure 12-B] Same as above. [Figure 13-A] The data provide A) images of beads from the titration experiment of Example 7. B) Graph showing the optimal range of signal was approximately 1:500 to 1:5000 (the lower range of the manufacturer's recommended range). [Figure 13-B] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0080] Microcapillary arrays have recently been used in approaches for high-throughput analysis and protein engineering with large numbers of biological samples, for example in an approach called "microcapillary single-cell analysis and laser extraction" or "μSCALE." See Chen et al. (2016) Nature Chem. Biol. 12:76-81; DOI:10.1038 / NCHEMBIO.1978. This approach relies on spatial separation of single cells within the microcapillary array, thus allowing repeated imaging, cell growth, and protein expression of separate samples within each microcapillary of the microcapillary array. Thus, this technique allows for massively parallel quantitative biochemical and biophysical measurements on millions of samples within the microcapillary array, for example in the analysis of millions of protein variants expressed from yeast, bacteria, or other suitable cells distributed across the array. Advantageously, this approach allowed for simultaneous time-resolved kinetic analysis of multiple samples, and sorting of those cells based on targeted phenotypic features.

[0081] The development of μSCALE methods and devices for quantitative biochemical and biophysical analysis of populations of biological variants has also been reported in US Patent Application Publication No. 2016 / 0244749(A1), which is incorporated herein by reference in its entirety. However, the extraction of the desired microcapillary contents by the μSCALE approach requires the inclusion of a radiation-absorbing material in each sample and the directing of electromagnetic radiation from a pulsed laser to this material, thus complicating the extraction method. In addition, to minimize the signal emitted from microcavities that lack the desired binding activity, early methods of screening biological variants in arrays of microcavities relied on adding microparticles to the aligned samples to partially or completely block the transmission of electromagnetic radiation into and out of the sample. See US Patent Application Publication No. 2014 / 0011690(A1). In some embodiments of the present disclosure, the screening method does not rely on these additional sample components or manipulations, thus simplifying and improving the efficiency of the screening technique.

[0082] In certain applications of these approaches, and as disclosed in more detail herein, the target molecule may be immobilized on a surface, such as a particle (e.g., a magnetic particle), a cell, or the surface of a microcapillary wall. The interaction of the mutant protein with the target molecule in these approaches may then be measured by a number of methods, including methods that utilize detectable antibodies and methods that measure detectable signals generated within the target cells. It will be appreciated that such methods may be used in high throughput screening to discover protein mutants that bind to target molecules, such as target molecules on cells or other surfaces.

[0083] Screening Methods Thus, in some embodiments, the present disclosure provides a method of screening a population of mutant proteins comprising the steps of: providing a microcapillary array comprising a plurality of microcapillaries, each microcapillary comprising a mutant protein, an immobilized target molecule, and a reporter element, wherein the mutant protein associates with the immobilized target molecule with a particular affinity; and Measuring a signal from the at least one reporter element indicative of association of the at least one mutant protein with the at least one immobilized target molecule to identify the at least one microcapillary of interest.

[0084] In these methods, the microcapillary array preferably comprises a plurality of longitudinally fused capillaries, such as fused silica capillaries, although any other suitable material may be used for the array.See, for example, PCT International Patent Publication Nos. WO2012 / 007537 and WO2014 / 008056, the entirety of which is incorporated herein by reference.Such an array can be manufactured, for example, by bundling millions or billions of silica capillaries and fusing them through a thermal process, although other suitable manufacturing methods can also be used. The melting process may include, for example, steps of: i) heating the capillary single draw glass drawn into a single clad fiber under tension; ii) making a capillary multi-draw single capillary from the single draw glass by bundling, heating, and drawing; iii) making a capillary multi-multi-draw multi-capillary from the multi-draw single capillary by additional bundling, heating, and drawing; iv) making a block assembly of drawn glass from the multi-multi-draw multi-capillary by stacking them into a pressing block; v) making a block pressing block from the block assembly by treating with heat and pressure; and vi) making a block forming block by cutting the block pressing block to a precise length (e.g., 1 mm).

[0085] In some embodiments, the method further comprises slicing the silica capillaries, thereby forming a very high density glass microcapillary array. In some embodiments, the microcapillary array may be cut to a height of about 1 millimeter, although shorter microcapillary arrays are contemplated, including arrays with heights of 10 μm or less. In some embodiments, longer microcapillary arrays are contemplated, including arrays with heights of 10 mm or more.

[0086] Such a process forms very high density microcapillary arrays suitable for use in the present methods. In an exemplary array, each microcapillary has a diameter of about 5 μm and about 66% open space (i.e., representing the lumen of each microcapillary). In some arrays, the percentage of the array that is open ranges from about 50% to about 90%, e.g., about 60-75%, such as the microcapillary array provided by Hamamatsu, which has an open area of ​​about 67%. In one particular example, a 10×10 cm array with 5 μm diameter microcapillaries and about 66% open space has about 330 million microcapillaries.

[0087] In various embodiments, the inner diameter of each microcapillary in the array ranges from about 1 μm to 500 μm. In some arrays, each microcapillary can have an inner diameter in the range of about 1 μm to 300 μm, optionally about 1 μm to 100 μm, further optionally about 1 μm to 75 μm, further optionally about 1 μm to 50 μm, and further optionally about 5 μm to 50 μm.

[0088] In some microcapillary arrays, the open area of ​​the array represents up to 90% of the open area (OA), so the number of microcapillaries per cm of array varies from about 4.6 to over 11 million when pore diameters vary from 1 μm to 500 μm. In some microcapillary arrays, the open area of ​​the array represents about 67% of the open area, so the number of microcapillaries per cm of array varies from about 3.4 to over 800,000 when pore diameters vary from 1 μm to 500 μm. In some embodiments, the pore size is 1 μm, 5 μm, 10 μm, 50 μm, 100 μm, 250 μm, 350 or 500 μm. In some embodiments, the pore size is 5 μm to 500 μm. In some embodiments, the pore size is 10 μm to 450 μm. In some embodiments, the pore size is 50 μm to 500 μm. In some embodiments, the pore size is 100 μm to 500 μm. In some embodiments, the pore size is 250 μm to 500 μm. In some embodiments, the pore size is 350 μm to 500 μm. In some embodiments, the pore size is 100 μm to 450 μm. In some embodiments, the pore size is 250 μm to 450 μm. In some embodiments, the number of microcapillaries per square cm of the array is about 400, 500, 1000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 20,000, 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, or 800,000. In some embodiments, the number of microcapillaries per square cm of the array varies between about 500 and 800,000. In some embodiments, the number of microcapillaries per square cm of the array varies between about 1000 and 700,000. In some embodiments, the number of microcapillaries per square cm of the array varies between about 2000 and 600,000. In some embodiments, the number of microcapillaries per square cm of the array varies between about 10,000 and 800,000. In some embodiments, the number of microcapillaries per square cm of the array varies between about 10,000 and 700,000. In some embodiments, the number of microcapillaries per square cm of the array varies between about 50,000 and 800,000. In some embodiments, the number of microcapillaries per square cm of the array varies between about 50,000 and 700,000. In some embodiments, the number of microcapillaries per square cm of the array varies between about 100,000 and 700,000. In some embodiments, the number of microcapillaries per square cm of the array ranges between about 100,000 and 600,000. In some embodiments, the number of microcapillaries per square cm of the array ranges between about 100,000 and 500,000. In some embodiments, the number of microcapillaries per square cm of the array ranges between about 500,000 and 800,000.

[0089] In one particular embodiment, microcapillary arrays can be fabricated by bonding billions of silica capillaries and then fusing them through a thermal process. Slices (0.5 mm or larger) are then cut to form very high aspect ratio glass microcapillary arrays. Arrays are also commercially available from Hamamatsu Photonics KK (Japan), Incom, Inc. (Massachusetts), Photonis Technologies, SAS (France) Inc., etc. In some embodiments, the microcapillaries of the array are closed at one end with a solid substrate attached to the array.

[0090] The microcapillary array of the present screening method can include any number of microcapillaries in the array. In some embodiments, the microcapillary array includes at least 100,000, at least 300,000, at least 1,000,000, at least 3,000,000, at least 10,000,000, or even more microcapillaries. In some embodiments, the array includes at least 100,000, at least 200,000, at least 300,000, at least 400,000, at least 500,000, at least 600,000, at least 700,000, at least 800,000, at least 1,000,000, at least 1,500,000, at least 2,000,000, at least 2,500,000, or at least 3,000,000 or more microcapillaries. The number of microcapillaries in the array is preferably selected having regard to the size of the mutant protein library to be screened.

[0091] As described above, each capillary in the microcapillary array used in the screening method comprises a mutant protein, an immobilized target molecule, and a reporter element, and the mutant protein is one of the population of mutant proteins that is subjected to the screening method. The population of mutant proteins can be any population of proteins that can be appropriately distributed in the microcapillary array. Ideally, the population of mutant proteins is distributed in the microcapillary array so that each microcapillary contains a small number of different mutant proteins, preferably a single different mutant protein per microcapillary. What is important is that the population of mutant proteins is selected in combination with the immobilized target molecule such that at least some proteins in the population can associate with the immobilized target molecule with a specific affinity, such that the association can be detected by measuring the signal from the reporter element.

[0092] The term "protein" as used herein refers to both full-length proteins or polypeptide sequences, and fragments thereof. Such fragments may include fragments that retain functional activity, such as, for example, binding activity. The terms "protein" and "polypeptide" are used interchangeably throughout this disclosure and include a chain of amino acids covalently linked via peptide bonds, where each amino acid in a polypeptide may be referred to as an "amino acid residue." The use of the term "protein" or "polypeptide" should not be considered limited to any particular length of polypeptide, e.g., any particular number of amino acid residues. The subject proteins may include proteins having non-peptide modifications, such as post-translational modifications including glycosylation, acetylation, phosphorylation, sulfation, etc., or other chemical modifications, such as alkylation, acetylation, esterification, PEGylation, etc. Additional modifications, such as the inclusion of unnatural amino acids within the polypeptide sequence or non-peptide bonds between amino acid residues, should also be considered within the definition of the term "protein" or "polypeptide."

[0093] The population of mutant proteins is preferably a population of proteins with small mutations, for example, each protein has a slightly different amino acid sequence.Therefore, the screening assay can identify mutant protein sequences with desirable properties.The screening can be carried out on a microscopic scale in very large quantities, so that a large number of mutant proteins can be assayed in a relatively short time.

[0094] The mutant proteins and / or mutant polypeptides may include, but are not limited to, secreted proteins. In some embodiments, the secreted proteins are derived from a recombinant protein and / or polypeptide library. In some embodiments, the secreted proteins are derived from a recombinant protein and / or polypeptide library. In some embodiments, the secreted proteins are derived from a recombinant protein and / or polypeptide library from a mammalian cell line. In some embodiments, the recombinant protein and / or polypeptide library comprises full-length mammalian antibodies. In some embodiments, the recombinant protein and / or polypeptide library comprises full-length mammalian antibodies, including IgG1, IgG2, and IgG4 antibodies and variants thereof. In some embodiments, the recombinant protein and / or polypeptide library comprises full-length human antibodies. In some embodiments, the recombinant protein and / or polypeptide library comprises full-length human antibodies, including IgG1, IgG2, and IgG4 antibodies. In some embodiments, the recombinant protein and / or polypeptide library comprises full-length mouse antibodies. In some embodiments, the recombinant protein and / or polypeptide library comprises full-length mouse antibodies, including IgG1, IgG2, and IgG4 antibodies. In some embodiments, the recombinant protein and / or polypeptide library comprises full-length rat antibodies. In some embodiments, the recombinant protein and / or polypeptide library comprises full length rat antibodies, including IgG1, IgG2, and IgG4 antibodies. In some embodiments, the recombinant protein and / or polypeptide library comprises antibody fragments (Fab). In some embodiments, the recombinant protein and / or polypeptide library comprises single chain variable fragments (scFv). In some embodiments, the recombinant protein and / or polypeptide library comprises natural protein ligands.In some embodiments, the recombinant protein and / or polypeptide library comprises natural protein ligands for a defined target protein and / or polypeptide.

[0095] In some embodiments, each microcapillary in the microcapillary array contains 0-5 different mutant proteins from the population of mutant proteins. In certain embodiments, each microcapillary in the microcapillary array contains 0-4, 0-3, 0-2, or even 0-1 different mutant proteins from the population of mutant proteins. It is understood that the different mutant proteins in the population of mutant proteins differ in their molecular structure, whether or not there are differences in their amino acid sequence or any other chemical modification of the protein.

[0096] It should be understood that each microcapillary typically contains many multiple copies of the same mutant protein, depending on the origin and expression level of the particular mutant protein (see below). In some embodiments, each microcapillary contains thousands, tens of thousands, hundreds of thousands, millions, billions, or even more molecules of a particular mutant protein, depending on how the mutant protein is delivered to or expressed in the microcapillary. In some embodiments, the mutant protein can bind to one, two, three, or four or more target molecules. In some embodiments, the mutant protein can bind to one target molecule. In some embodiments, the mutant protein can bind to two target molecules. In some embodiments, the mutant protein can bind to three target molecules. In some embodiments, the mutant protein can bind to four target molecules. In some embodiments, the mutant protein can bind to more than four target molecules. In some embodiments, this assay can alternatively be used to screen for antibodies that bind to both mouse and human (or other animal combination) variants of a target protein, i.e., to discover "cross-reactive" antibodies. For example, the presence of stained cells and the presence of stained beads in the microcapillary indicates the presence of an antibody that binds to the "target protein" (e.g., mouse target) and also binds to the "target protein analog" (e.g., human target) to identify antibodies that bind to both mouse and human targets. For example, the presence of stained cells and the presence of stained beads in the microcapillary indicates the presence of an antibody that binds to the "target protein" (e.g., cynomolgus target) and also binds to the "target protein analog" (e.g., human target) to identify antibodies that bind to both cynomolgus and human targets.

[0097] The population of mutant proteins is typically generated using a genetic library in a biological expression system, such as an in vitro (i.e., cell-free) expression system or an in vivo or cellular expression system. Exemplary cellular expression systems include, for example, an animal system (e.g., a mammalian system), a fungal system (e.g., a yeast system), a bacterial system, an insect system, or a plant system. In certain embodiments, the expression system is a mammalian system or a yeast system. The expression system, whether cellular or acellular, typically includes a library of genetic material that encodes the population of mutant proteins. Cellular expression systems offer the advantage of being able to grow and propagate cells with a desired phenotype, e.g., cells expressing a particular mutant protein of interest, such as a mutant protein that can associate with an immobilized target molecule with high affinity, thus simplifying the identification and characterization of the protein of interest expressed by the cells. In some embodiments, the biological expression system includes a mammalian cell line. In some embodiments, the mammalian cell line is selected from the group consisting of CHO-K1, CHO-S, HEK293T, and / or any derivative of these cell types. In some embodiments, the mammalian cell line is CHO-K1. In some embodiments, the mammalian cell line is CHO-S. In some embodiments, the mammalian cell line is HEK293T. In some embodiments, the mammalian cell line is selected from the group consisting of human, mouse, and / or rat hybridoma cell lines. In some embodiments, the mammalian cell line is a human hybridoma cell line. In some embodiments, the mammalian cell line is a mouse hybridoma cell line. In some embodiments, the mammalian cell line is a rat hybridoma cell line.

[0098] Gene libraries encoding large populations of mutant proteins are well known in the field of biotechnology. Such libraries are often utilized in systems that rely on the process of directed evolution to identify proteins with advantageous properties, such as high affinity binding to a target molecule, stability, high expression, or specific spectroscopic activity, e.g., fluorescence or enzymatic activity. Often, the library contains genetic fusions with sequences from the host expression system, e.g., fragments of proteins that direct subcellular localization, and the expression population of mutant fusion proteins is directed by the targeting fragment to a specific location in a cell or viral particle for activity screening of the mutant protein population. As is well known in the art, routine biotechnology techniques can be used to generate large numbers of mutant proteins (e.g., up to 10 6 Mutant, 10 8 Mutant, 10 10 Mutant, 10 12 A library of variants (mutants, or even more variants) can be generated. Such libraries can include any of the variant proteins described herein, including antibodies, antibody fragments, single chain variable fragments, or natural protein ligands.

[0099] Thus, in some embodiments, the mutant proteins are soluble proteins, e.g., soluble proteins secreted by a cellular expression system. Exemplary soluble mutant proteins include antibodies and antibody fragments, alternative protein scaffolds, such as disulfide-bonded peptide scaffolds, extracellular domains of cell surface receptor proteins, receptor ligands, e.g., G protein-coupled receptor ligands, other peptide hormones, lectins, and the like. Advantageously, the mutant proteins with the desired binding activity and the cells expressing them are co-localized in the same microcapillary throughout the assay, so that the mutant proteins screened for binding activity in the present method do not need to be covalently linked to the cells or viruses expressing them in order to be identified after the screening assay. Isolation of the contents of the desired microcapillary, followed by growth of the cell or virus clone responsible for expression of the desired mutant protein, thereby allows the protein to be identified and characterized. Unlike screening assays in which the mutant protein of interest is presented by fusion of the protein to a molecule on the surface of a cell or virus particle, the mutant proteins identified in the present screening method do not need to be modified in any way after their identification. Thus, the activities of the mutant proteins observed in the screen are more likely to represent the actual activities of those proteins in their subsequent applications.

[0100] However, in other embodiments, it may be desirable for the mutant protein to be a membrane-bound protein, for example, a protein that remains bound to the surface of a cell or a viral particle in an expression system. Screening for cell-bound mutant proteins may be desirable when the mutant protein and its target molecule mediate the interaction between two cells in a living tissue. The ability to screen for cell-bound mutant proteins may also be desirable when screening for interactions with traditionally "undruggable" protein targets, such as, for example, G-protein coupled receptors or ion channels.

[0101] In addition to mutant proteins, each microcapillary in the microcapillary array of the present screening method also contains an immobilized target molecule. The immobilized target molecule serves as a potential binding partner for the mutant protein in the screening assay. Unlike a population of mutant proteins, where each microcapillary ideally contains mutant proteins with slightly different sequences, the immobilized target molecule ideally has the same molecular structure in each microcapillary of the array. In some embodiments, there is no binding or other interaction between the mutant protein and another agent or molecule (e.g., a target molecule) prior to the addition of the mutant protein to the microcapillary. In some embodiments, the interaction between the mutant protein and the target molecule occurs within the microcapillary and / or microcavity.

[0102] In some embodiments, the target molecule is a target protein or polypeptide, a target nucleic acid, a target carbohydrate, a target lipid, or a combination of two or more of these target molecules. For example, in some embodiments, the target molecule can be a lipid-modified protein or a glycosylated protein. In some embodiments, the target molecule is immobilized on a surface. In more specific embodiments, the target molecule is immobilized on the surface of a cell, such as a target cell, on the surface of a bead, on the surface of a microcapillary wall, or on another suitable surface. In other more specific embodiments, the target molecule is a natural protein, such as a natural protein immobilized on the surface of a cell. In yet other more specific embodiments, the target molecule is immobilized on a surface configured to settle in a microcapillary by gravitational sedimentation. In some embodiments, one, two, three, four, or more target molecules are used to identify mutants that bind to one, two, three, four, or more target molecules. In some embodiments, the target molecules are separately contained in separate, different microcapillaries. In some embodiments, the target molecules are separately contained in separate, different microcapillaries in a single array. In some embodiments, the target molecules are separately contained in separate, different microcapillaries in one or more arrays. In some embodiments, the target molecules are contained together in a single microcapillary. In some embodiments, the target molecules are contained together in a single microcapillary in a single array. In some embodiments, the one, two, three, or four or more target molecules to which the variants bind are derivatives or variants of the original target molecule, including chemical modifications, secondary post-translational modifications, or sequence identity variants (e.g., variants having 70%, 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to the original nucleic acid or amino acid target sequence).

[0103] As mentioned above, in the disclosed method, the mutant protein associates with the immobilized target molecule with a specific affinity in the microcapillary. Importantly, such affinity must be strong enough for the mutant protein of interest such that the association can be measured by a signal from the reporter element. As will be appreciated by those skilled in the art, binding affinity is typically measured using a dissociation constant (K d ), with the lower the dissociation constant, the higher the affinity. In some embodiments, the association of the mutant protein of interest with the immobilized target molecule exhibits a dissociation constant in the millimolar to micromolar range. In certain embodiments, the association is in the micromolar to high nanomolar (i.e., 10 -6 M~10 -8 In more specific embodiments, the association exhibits a dissociation constant of from low nanomolar to high picomolar (i.e., 10 -8 M~10 -10 In still more specific embodiments, the association is in the picomolar range (i.e., 10 -10 M~10 -12 M), or even lower. In some embodiments, the first cell expresses and secretes the mutant protein or polypeptide and the second cell contains the target, such that the first cell binds to the second cell. In some embodiments, the second cell expresses the target. In some embodiments, the second cell is labeled with the target. In some embodiments, the first cell binds to the second cell in a microcapillary. In some embodiments, the first cell binds to the second cell in a microcapillary and / or microcavity.

[0104] In addition to the mutant protein and the immobilized target molecule, each microcapillary in the microcapillary array of the present screening method also contains a reporter element. Importantly, the reporter element provides a measurable signal indicative of the association of the mutant protein with the immobilized target molecule, and thus serves to identify the microcapillary containing the mutant protein of interest.

[0105] In some embodiments, the reporter element is a labeled antibody or other molecule capable of binding to each mutant protein in the population of mutant proteins. More specifically, the reporter element is a fluorescently labeled antibody or other binding molecule.

[0106] In some embodiments, the labeled antibody is a labeled primary antibody or a labeled secondary antibody. For the purposes of this disclosure, a primary antibody is typically considered to be an antibody that directly binds to an antigen of interest, and a secondary antibody is typically considered to be an antibody that binds to a constant region on a primary antibody for the purpose of labeling the primary antibody. Thus, secondary antibodies are frequently labeled with a fluorophore or other detectable label, or with an enzyme that can generate a detectable signal. They are generally specific to a primary antibody from a different species. For example, as will be understood by those skilled in the art, goats or other animal species can be used to make secondary antibodies against almost any primary antibody other than those from mice, chickens, rabbits, or that animal species. In certain embodiments, the labeled antibody is a fluorescent antibody or an enzyme-linked antibody.

[0107] In some of the embodiments of the method, for example in the screening method shown in Figures 1A-1C, the mutant protein mediates the association of the reporter element with a target molecule, in this example a target molecule on the surface of a target cell. As shown in Figure 1B, if the mutant protein (referred to here as a "secreted protein") has sufficient affinity for its target molecule on the target cell, the mutant protein will associate with the target cell under the conditions of the microcapillary solution. The reporter element (referred to here as a "fluorescent detection antibody") ideally binds to the mutant protein at an epitope that does not affect the affinity of the mutant protein for the target molecule, as shown in Figure 1C.

[0108] As will be appreciated by those skilled in the art, when soluble reporter elements such as fluorescent antibodies are used in the present screening methods, the signal emitted by any excess reporter elements that remain free in solution in the microcapillary (i.e., not bound to mutant proteins or bound to mutant proteins that are not bound to target molecules) should not be so high as to overwhelm the signal of reporter elements associated with target molecules via mutant proteins (see, for example, the unassociated fluorescent detection antibody shown in Figure 1C). However, such background signals can be minimized by limiting the concentration of labeled antibodies or other reporter elements in the microcapillary solution. Furthermore, when signals from the screening methods are measured using a fluorescent microscope, background signals from reporter elements not associated with target molecules can be minimized by configuring the microscope to image a relatively narrow depth of field surrounding the location of the target molecules (e.g., the bottom of the microcapillary if the target cells have settled there by sedimentation gravity).

[0109] In other embodiments, the reporter element is an intracellular reporter element that generates a detectable signal in association with a binding event, such as, for example, the association of a mutant protein with an immobilized target molecule, such as a receptor or other molecular target on the surface of a cell. In these embodiments, the reporter element may include an entire cellular pathway, such as, for example, an intracellular signaling pathway. Such pathways should contain, or be engineered to contain, a detectable signal as a downstream readout of the pathway. In contrast to the assays shown in Figures 1A-1C, in which the detectable signal is bound to the outer surface of the target cell, the detectable signal in these embodiments will typically occur inside the target cell.

[0110] Many intracellular signaling pathways have been developed for use in high-throughput screening assays, particularly in drug discovery screening, and can be adapted for use in the present assay. See, for example, Michelini et al. (2010) Anal. Bioanal. Chem. 398:227-38. In particular, any cellular assay in which a binding event with a target molecule on the cell surface results in the generation of a measurable signal, particularly a fluorescent signal, can be used as a reporter element in the present assay. Preferably, cells can be engineered to express a target molecule of interest on their surface, such that binding of a particular mutant protein to the target molecule and the resulting activation of an intracellular signaling pathway results in the generation of a detectable signal from the reporter element, thus allowing the identification of the microcapillary as a positive hit. Expression of green fluorescent protein (GFP), or any of a wide variety of mutant fluorescent proteins, is often used as a readout in such cellular assays and can serve as the endpoint of the reporter element in the present method. Alternatively, as will be well understood by those skilled in the art, a readout of signaling can be provided by luciferase or other related enzymes that generate a bioluminescent signal. See, for example, Kelkar et al. (2012) Curr. Opin. Pharmacol. 12:592-600. Reporter elements can also include RFP (red fluorescent protein) and YFP (yellow fluorescent protein), as well as variants thereof. Other well-known enzyme reporters from bacterial and plant systems include β-galactosidase, chloramphenicol acetyltransferase, β-glucuronidase (GUS), etc., which can be adapted for use in the present screening assays using appropriate chromogenic substrates. Transcriptional reporters using firefly luciferase and GFP have been widely used to study the function and regulation of transcription factors. They can be similarly adapted for use in the present screening assays.Exemplary intracellular signaling systems are commercially available, for example, Qiagen's Cignal™ Reporter Assay kits available with either luciferase or GFP readouts (see, for example, www.sabiosciences.com / reporterassays.php). Such systems can be appropriately redesigned for use in the present screening methods.

[0111] It should be understood that the mutant protein expression system, particularly when the expression system is a cellular expression system, may be combined with immobilized target molecules and reporter elements (or suitable components, such as cellular components involved in the creation of the immobilized target molecules and / or reporter elements) prior to expression of the mutant protein and / or prior to delivery of the assay mixture to the array of microcapillaries. Such an approach advantageously allows for flexibility and control in the timing of interactions between components, compared to prior art microcapillary screening systems in which all components of the screening assay are typically mixed in a static format and loaded into the microcapillary. In contrast, the present method allows for some or all of the components of the binding assay to be created in situ within the microcapillary by allowing proliferation of the cellular components, expression of the genetic components, or both. In some embodiments, cell culture medium and / or growth agents are used to maintain the health of the cells during the assay process. In some embodiments, components that promote the metabolic health of the cells are included.

[0112] It should also be understood that the concentration of each component of the screening assay in the microcapillary, including the concentration of the mutant protein, the concentration of the immobilized target molecule, and the concentration of the reporter element, can be adjusted as desired in the assay to obtain optimal results. In particular, it may be desirable to adjust the concentration of the mutant protein and / or the immobilized target molecule to achieve a desired level of association between these components. The level of association also depends on the specific affinity between these components, with higher affinity resulting in a higher level of association for a given concentration of the components, and lower affinity resulting in a lower level of association of the components for a given concentration. As will be appreciated by those skilled in the art, the concentration of the reporter element may be similarly adjusted to achieve an optimal level of signal output. In some embodiments, the reporter element used includes a secondary antibody, including those commercially available. In some embodiments, the dilution range is 1:200 to 1:2000. In some embodiments, the dilution range is 1:300 to 1:2000. In some embodiments, the dilution range is 1:300 to 1:1500. In some embodiments, the dilution range is 1:400 to 1:1500. In some embodiments, the dilution range is 1:500 to 1:1500. In some embodiments, the dilution range is 1:200 to 1:1000. In some embodiments, the dilution range is 1:500 to 1:1000. In some embodiments, the dilution range is 1:1000 to 1:2000. In some embodiments, the dilution range is 1:1500 to 1:2000. In some embodiments, the dilution is 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, 1:1000, 1:1500, or 1:2000. In some embodiments, the fluorophore is AlexaFluor3, AlexaFluor5, AlexaFluor350, AlexaFluor405, AlexaFluor430, AlexaFluor488, AlexaFluor500, AlexaFluor514, AlexaFluor532, AlexaFluor546, AlexaFluor555, AlexaFluor568,Fluorophores may include, but are not limited to, AlexaFluor594, AlexaFluor610, AlexaFluor633, AlexaFluor647, AlexaFluor660, AlexaFluor680, AlexaFluor700, and AlexaFluor750 (Molecular Probes AlexaFluor dyes available from Life Technologies, Inc. (USA)). In some embodiments, fluorophores may include, but are not limited to, Cy dyes, including Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, and Cy7 (available from GE Life Sciences or Lumiprobes). In some embodiments, fluorophores may include, but are not limited to, DyLight350, DyLight405, DyLight488, DyLight550, DyLight594, DyLight633, DyLight650, DyLight680, DyLight750, and DyLight800 (available from Thermo Scientific (USA)). In some embodiments, the fluorophore is selected from the group consisting of FluoProbes 390, FluoProbes 488, FluoProbes 532, FluoProbes 547H, FluoProbes 594, FluoProbes 647H, FluoProbes 682, FluoProbes 752 and FluoProbes 782, AMCA, DEAC (7-diethylaminocoumarin-3-carboxylic acid); 7-hydroxy-4-methylcoumarin-3; 7-hydroxycoumarin-3; MCA (7-methoxycoumarin-4-acetic acid); 7-methoxycoumarin-3; AMF (4'-(aminomethyl)fluorescein); 5-DTAF (5-(4,6-dichlorotriazinyl)aminofluorescein); 6-DTAF (6-(4,6-dichlorotriazinyl)aminofluorescein); 6-FAM (6-carboxyfluorescein),5(6)-FAM cadaverine;5-FAM cadaverine;5(6)-FAM ethylenediamine;5-FAM ethylenediamine;5-FITC (FITC isomer I; Fluorescein-5-isothiocyanate);5-FITC cadaverine;Fluorescein-5-maleimide;5-IAF (5-iodoacetamidofluorescein);6-JOE (6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein);5-CRl l0 (5-carboxyrhodamine 110);6-CRl l0(6-carboxyrhodamine 110);5-CR6G(5-carboxyrhodamine 6G);6-CR6G(6-carboxyrhodamine 6G);5(6)-carboxyrhodamine 6G cadaverine;5(6)-carboxyrhodamine 6G ethylenediamine;5-ROX(5-carboxy-X-rhodamine);6-ROX(6-carboxy-X-rhodamine);5-TAMRA(5-carboxytetramethylrhodamine);6-TAMRA(6-carboxytetramethylrhodamine);5-TAMRA cadaverine;6-TAMRA cadaverine;5-TAMRA ethylenediamine;6-TAMRA ethylenediamine;5-TMR C6 maleimide;6-TMR C6 maleimide;TR The reporter elements used may include, but are not limited to, C2 maleimide; TR cadaverine; 5-TRITC; G isomer (tetramethylrhodamine-5-isothiocyanate); 6-TRITC; R isomer (tetramethylrhodamine-6-isothiocyanate); dansylcadaverine (5-dimethylaminonaphthalene-l-(N-(5-aminopentyl))sulfonamide); EDANS C2 maleimide; fluorescamine; NBD; and pyrromethene, and derivatives thereof. In some embodiments, the reporter element used may be a donkey anti-goat IgG secondary antibody labeled with AlexaFluor633.

[0113] In some embodiments, each microcapillary in the microcapillary array of the present screening method further comprises one or more agents for improving the viability of the cell expression system. Specifically, the agent or agents are included to prevent cell damage during the step of isolating the contents of the microcapillary of interest, for example, by a laser pulse (see below). In preferred embodiments, the agent is methylcellulose (e.g., 0.001-10% by weight), dextran (e.g., 0.5-10% by weight), Pluronic F-68 (e.g., 0.01-10% by weight), polyethylene glycol ("PEG") (e.g., 0.01-10% by weight), polyvinyl alcohol ("PVA") (e.g., 0.01-10% by weight), or the like. Alternatively or in addition, each microcapillary in the microcapillary array of the present screening method may further comprise a growth additive, such as, for example, 50% conditioned growth medium, 25% standard growth medium, or 25% serum. In some embodiments, the conditioned growth medium is conditioned for 24 hours. In some embodiments, the added agent is insulin, transferrin, ethanolamine, selenium, insulin-like growth factor, or a combination of these agents, or a combination of any of the above agents.

[0114] The screening method of the present disclosure further comprises a step of measuring a signal from at least one reporter element that indicates the association of at least one mutant protein with at least one immobilized target molecule to identify at least one microcapillary of interest. In some embodiments, the signal measured is a fluorescent signal, an absorbance signal, a bright-field signal, or a dark-field signal, a phase contrast signal, etc. Thus, the measuring step can be performed by a suitable detector device, for example, a device that can detect electromagnetic radiation or any other suitable signal. In certain embodiments, the measuring step is performed by a microscope, such as a fluorescent microscope or other microscope configured to detect the above-mentioned signals.

[0115] It should be understood that in a preferred embodiment, the microcapillaries utilized in the present screening method do not contain microparticles capable of suppressing the transmission of electromagnetic radiation. In other words, the microcapillaries are preferably completely transparent to the electromagnetic radiation incident on the microcapillary array, particularly along the longitudinal axis of the microcapillary. In another preferred embodiment, the microcapillaries of the present screening method do not contain magnetic microparticles or beads. In yet another preferred embodiment, the microcapillaries of the present screening method do not contain microparticles, magnetic microparticles, or magnetic beads capable of suppressing the transmission of electromagnetic radiation.

[0116] In other preferred embodiments, the microcapillaries utilized in the present screening methods do not contain electromagnetic radiation absorbing materials, however, it should be understood that components of reporter elements involved in generating a measurable signal in the screening methods, such as fluorophores on fluorescent antibodies, are not to be considered electromagnetic radiation absorbing materials for the purposes of this aspect of the invention.

[0117] In some embodiments, the screening method further comprises a step of isolating the contents of the microcapillary of interest. In certain embodiments, the contents of the microcapillary of interest are isolated by pulsing the microcapillary of interest with a laser. More specifically, the laser can be a diode laser or a diode-pumped Q-switched Nd:YLF laser. In some embodiments, the laser can be directed at the water-glass interface between the microcapillary wall and the sample contained in the microcapillary. Without intending to be bound by theory, it is believed that firing a UV laser at this interface can break the meniscus / water surface tension that normally holds the sample in the microcapillary, thus allowing the sample to fall from the array by the force of gravity. In other embodiments, the contents of the microcapillary of interest are isolated by laser-induced expansion by steam force. In some embodiments, the contents of the microcapillary are isolated by breaking the glass of the microcapillary itself.

[0118] In some embodiments, the microcapillary screening method of the present invention allows for screening of reactions and / or interactions (including binding interactions) between mutant proteins and target molecules that occur within minutes of adding the components to the microcapillary. In some embodiments, the reaction and / or interaction between the mutant protein and the target molecule occurs and / or is detectable within about 1 minute to about 10 minutes. In some embodiments, the reaction and / or interaction between the mutant protein and the target molecule occurs and / or is detectable within about 1 hour to about 6 hours. In some embodiments, the reaction and / or interaction occurs within about 1 hour, about 2 hours, about 4 hours, about 6, about 10 hours, about 12 hours, about 16 hours, about 24 hours, about 36 hours, or about 48 hours. hours, minutes to about 10 minutes. In some embodiments, the reaction and / or interaction between the mutant protein and the target molecule occurs and / or is detectable within a time period such that the cells in the microcapillary are viable and healthy. In some embodiments, the reaction and / or interaction between the mutant protein and the target molecule occurs and / or is detectable within a period of time such that the cells within the microcapillary are viable. In some embodiments, the cells are allowed to grow after removal from the microcapillary and / or microcavity. In some embodiments, the cells are viable after removal from the microcapillary and / or microcavity. In some embodiments, the reaction and / or interaction between the mutant protein and the target molecule occurs within the microcapillary.

[0119] Systems for screening According to another aspect of the invention there is provided a system for screening a population of mutant proteins comprising: An array comprising a plurality of microcapillaries, each of which contains a mutant protein, an immobilized target molecule, and a reporter element, and the mutant protein associates with the immobilized target molecule with a specific affinity. The components of these screening devices are described in detail above, and any of them can be incorporated into the system for screening.

[0120] In some embodiments, the screening system further comprises a light source and a detector. The light source and the detector are selected according to the specific reporter element used in the screening system. For example, if the reporter element generates a fluorescent signal, the light source provides an excitation light of a suitable wavelength to excite the fluorescent probe. Similarly, the detector is selected to be sensitive to the wavelength of light emitted by the fluorescent probe. As will be understood by those skilled in the art, the light source and the detector can be components of a microscope, such as a fluorescent microscope, or they can be separate devices.

[0121] In some embodiments, the screening system further comprises an extraction device, such as a diode laser, a diode-pumped Q-switched laser, or other suitable components for isolating the contents of the microcapillary of interest.

[0122] An exemplary microscope for screening a population of mutant proteins according to the present method is shown in the drawings in Figures 6A-6E. Figure 6A is a top perspective view of the microscope, showing both the array holding stage and the sample collection stage. Figure 6B shows a front view of the device. Figure 6C shows a view from the right side. A close-up view of the right side of the device is provided in Figure 6D, detailing the relationship between the array holding stage and the sample collection stage. Figure 6E provides an exploded view of the various components of a multi-stage sample collection microscope suitable for use in the present screening system.

[0123] It will be readily apparent to those skilled in the relevant art that other suitable modifications and adaptations may be made to the methods and applications described herein without departing from the scope of the present invention or any of its embodiments. Having described the present invention in detail, the present invention will be more clearly understood by reference to the following examples, which are not intended to limit the present invention but are for illustrative purposes only. In some embodiments, any aspect disclosed in the method section above can also be readily applied to the system of the present invention. The system of the present invention can be used with any of the methods described herein.

[0124] Exemplary embodiments The present application provides a method for screening a population of mutant proteins comprising the steps of: providing a microcapillary array comprising a plurality of microcapillaries, each microcapillary comprising a mutant protein, an immobilized target molecule, and a reporter element, wherein the mutant protein associates with the immobilized target molecule with a particular affinity; and Measuring a signal from the at least one reporter element indicative of association of the at least one mutant protein with the at least one immobilized target molecule to identify the at least one microcapillary of interest.

[0125] In some embodiments, the mutant protein is expressed by an expression system.

[0126] In some embodiments, the expression system is a cell-free expression system.

[0127] In some embodiments, the expression system is a cellular expression system.

[0128] In some embodiments, the cellular expression system is animal-, fungal-, bacterial-, insect-, or plant-based.

[0129] In some embodiments, the cell expression system is a yeast system.

[0130] In some embodiments, the mutant protein is a soluble protein.

[0131] In some embodiments, the target molecule is a target protein or polypeptide, a target nucleic acid, a target carbohydrate, or a combination of each.

[0132] In some embodiments, the target molecule is immobilized on a surface.

[0133] In some embodiments, the surface is the surface of a cell.

[0134] In some embodiments, the target molecule is a naturally occurring protein.

[0135] In some embodiments, the surface is the surface of a bead.

[0136] In some embodiments, the surface is a surface of a microcapillary wall.

[0137] In some embodiments, the surface is a surface configured to settle into the microcapillary by gravitational settling.

[0138] In some embodiments, the reporter element is a labeled antibody or other binding molecule.

[0139] In some embodiments, the labeled antibody or other binding molecule is a fluorescently labeled antibody or other binding molecule.

[0140] In some embodiments, the labeled antibody is a primary antibody or a secondary antibody.

[0141] In some embodiments, the labeled antibody or other binding molecule is an enzyme-linked antibody or other binding molecule.

[0142] In some embodiments, the reporter element is activated within the cell and the target molecule is immobilized on the surface of the cell.

[0143] In some embodiments, the reporter element comprises green fluorescent protein or a mutant.

[0144] In some embodiments, the signal is a fluorescent signal, an absorbance signal, a bright field signal, or a dark field signal.

[0145] In some embodiments, each microcapillary in the microcapillary array contains between 0 and 5 mutant proteins from a population of mutant proteins.

[0146] In some embodiments, the microcapillary array comprises at least 100,000, at least 300,000, at least 1,000,000, at least 3,000,000, or at least 10,000,000 microcapillaries.

[0147] In some embodiments, each microcapillary further comprises an agent for improving the viability of the cell expression system.

[0148] In some embodiments, the agent is methylcellulose, dextran puronic F-68, polyethylene glycol, or polyvinyl alcohol.

[0149] In some embodiments, the agent is a growth medium.

[0150] In some embodiments, the signal is measured by an optical detector.

[0151] In some embodiments, the signal is measured by microscopy.

[0152] In some embodiments, the method further comprises isolating the contents of the microcapillary of interest.

[0153] In some embodiments, the contents of a microcapillary of interest are isolated by pulsing the microcapillary of interest with a laser. EXAMPLES

[0154] Example 1. Screening for secreted EGFR binding proteins 1A-1C show an exemplary method for screening soluble proteins, in this case immobilized target proteins, that can associate with a cell surface protein (e.g., epidermal growth factor receptor ("EGFR")) as an immobilized target molecule. FIG. 1A (left panel) shows a target cell expressing EGFR on its surface. Also shown are "library-expressing cells" expressing a population of mutant proteins, and a number of "fluorescent detection antibodies" in the microcapillary solution. A bottom view of the microcapillary array is shown in the right panel.

[0155] This screening assay consists of the following components for each microcapillary: 1. Cells that secrete a mutant protein of interest ("library-expressing cells"). The mutant protein of interest is preferably a member of a population of mutant proteins, i.e. a protein library. 2. Target protein immobilized on the surface of a "target cell." In this example, the target protein is a natural cell surface receptor (i.e., EGFR). However, alternatively, the target protein may be immobilized on another surface, such as the surface of a bead or the surface of the microcapillary itself. 3. Reporter Elements In this example, the reporter element corresponds to a fluorescently labeled antibody specific for the secreted protein (i.e., a "fluorescent detection antibody"). The antibody specifically localizes to an epitope on the secreted protein, but ideally does not interfere with binding of the secreted protein to the target protein on the target cell. Alternatively, the reporter element may be a signaling pathway within a cell expressing the target protein: if the secreted mutant protein binds to the target protein on the cell surface and activates a signaling pathway within the target cell, the binding interaction will generate a fluorescent signal within the cell (not shown). 4. Reaction Buffer a. Can be a medium for library expressing cells or target cells (e.g., such a medium can be a hybridoma medium, including, for example, that available from ThermoFisher; thermofisher.com / order / catalog / product / 11279023; see World Wide Web at CD Hybridoma Medium). b. Can be a mammalian imaging solution (eg, such an imaging solution can be an optically clear physiological solution buffered with HEPES at pH 7.4).

[0156] Show me how Step 1: Add all components to a microcapillary (see Figure 1A).

[0157] Step 2: Specific "secreted proteins" are expressed in the microcapillary by the library-expressing cells. Secreted protein variants capable of binding to the target protein are localized to the target cell surface as shown (see Figure 1B).

[0158] Step 3: The fluorescent detection antibody associated with the bound secreted protein variant is observed associated with the target cell in the specific microcapillary (see Figure 1C).

[0159] Detailed explanation and example data: To demonstrate this method, a yeast vector library was generated that expressed proteins designed to bind to EGFR on human cancer cells. In this library, some yeast mutants were able to express the proteins, while others were unable to express the proteins. Yeast cells, cancer cells, and fluorescent antibodies against the expressed proteins were added to the microcapillary. After 18 hours, the microcapillary array was imaged. Further details and results of the screening are provided in Example 3 below.

[0160] Example 2. Hybridoma screening for mammalian cells General Background Current methods for screening binding interactions between proteins or other target molecules typically rely on the use of "display" methods, such as phage display, bacterial display, yeast display, mammalian display, or viral display. In display methods, libraries of genes encoding protein variants are expressed on the surface of cells or phages. The protein variants are incubated with soluble forms of the target molecule to identify protein variants capable of binding to the target. The library can be screened by panning or fluorescence-activated cell sorting ("FACS"). Such assays have two main constraints: 1) the engineered protein is typically tethered to a display platform, and 2) it is usually advantageous for a soluble form of the target molecule to be present. Thus, it can be difficult to develop reliable assays for mutant proteins that bind to many target molecules, especially membrane proteins such as G protein-coupled receptors and other such receptors.

[0161] Hybridoma screening for mammalian cells To identify antibody variants that specifically bind to a target molecule, the hybridomas (which secrete the antibody variants) were added to a cancer cell line that expressed high levels of EGFR as the target molecule. A labeled antibody specific for the secreted antibody was then added. material: cell: Mouse hybridoma A431 target cells (a human cancer cell line expressing high levels of EGFR) Detection antibody: Anti-mouse secondary antibody conjugated with Alexa488 (fluorophore) Cell Culture Media DMEM-10% fetal bovine serum DMEM-10% horse serum

[0162] Growth and preparation of cell lines Mouse hybridoma cells were cultured in complete medium (Dulbecco's modified Eagle medium with 10% horse serum). Hybridoma cells were washed twice with PBSA and suspended in complete medium at 600 cells / μL. A431 cells were cultured in complete medium (Dulbecco's modified Eagle medium with 10% fetal bovine serum). A431 cells were washed twice with PBSA and stained with LiveGreen fluorescent signal. A431 cells were then suspended in complete medium with hybridoma at a final concentration of 1800 cells / μL.

[0163] Assay setup After mixing the two cell types, a detection antibody was added to the reaction mixture: secondary (anti-mouse Alexa488) at a 1:100 dilution. This reaction mixture was then loaded onto a corona-treated microcapillary array (40 μm diameter, 1 mm thick) that had been sterilized with ethanol. A 2 mm thick slab of 1% weight / volume agarose was placed over the array to help prevent evaporation. After each time period, the samples were imaged under a fluorescent microscope and a brightfield microscope.

[0164] Sample data: Figures 2A-2C show images of subsections of the microcapillary array showing either all cells (Figure 2A, brightfield signal), A431 target cells (Figure 2B, LiveGreen signal), or cells labeled with a fluorescent anti-mouse secondary antibody (Figure 2C, Ab-a555 signal). Microcapillaries containing hybridoma cells expressing an antibody specific for EGFR are indicated by two arrows in each image.

[0165] Figure 3 shows images of a microcapillary containing both A431 target cells and hybridoma cells over a 4-hour incubation, where the antibody binding signal to the A431 target cells increased over the time course of the assay as mouse antibodies specific for EGFR were produced (center panel). LiveGreen staining of the A431 target cells decreased over the same period (right panel).

[0166] Example 3. Yeast library screening against mammalian cells To determine the best secretory yeast plasmid vector, a yeast vector library was generated expressing a scaffold protein designed to bind to EGFR on the cancer cell surface. The library contained yeast cells with various soluble expression levels of the scaffold protein. Using the described assay, the mutant expression library was screened to recover a plasmid vector that highly expressed the desired scaffold protein. In this experiment, the secreted scaffold had a c-Myc tag, which can be labeled with a fluorescently labeled antibody. material: cell: Yeast secreted library of scaffold proteins A431 cells (a human cancer cell line that expresses high levels of EGFR) Detection antibody: Chicken anti-c-Myc Alexa488-labeled anti-chicken secondary antibody Cell Culture Media: DMEM-10% FBS SD-CAA Minimal Yeast Medium Reaction Buffer: SD-CAA Minimal Yeast Medium

[0167] method: Growth and preparation of cell lines The yeast library was grown in SD-CAA minimal yeast medium (20 g glucose, 6.7 g Difco yeast nitrogen base, 5 g Bacto casamino acids, 5.4 g Na2HPO4, 8.56 g NaH2PO4H2O, dissolved in deionized H2O to a volume of 1 liter). After growth, yeast cells were washed twice with PBSA (phosphate buffered saline + 1 mg / ml BSA) and suspended in SD-CAA to a final concentration of 2,400 cells / μL.

[0168] A431 cells were cultured in complete medium (Dulbecco's modified Eagle's medium containing 10% fetal bovine serum). A431 cells were washed twice with PBSA and suspended in SD-CAA containing yeast cells at a final concentration of 600 cells / μL.

[0169] Assay setup After mixing the two cell types, two antibodies were added to the reaction mixture: an unlabeled primary antibody (chicken anti-c-Myc) at a 1:250 dilution and a labeled secondary antibody (anti-chicken Alexa488) at a 1:200 dilution. This reaction mixture was then loaded onto a corona-treated microcapillary array (40 μm diameter, 1 mm thick) that had been sterilized with ethanol. A 2 mm thick slab of 1% weight / volume agarose was placed over the array to help prevent evaporation. After 18 hours of growth, samples were imaged under a fluorescent microscope and a brightfield microscope.

[0170] Microcapillary array extraction The contents of the desired capillaries were extracted using a Triton UV laser. The laser was operated for 18 ± 2 ms (n = 5 measurements) to deliver a train of 2.5 kHz pulses with a total energy of approximately 100 μJ. The contents of the microcapillaries were extracted onto a glass coverslip, which was then placed into yeast growth medium (liquid medium or agar plates) to grow the extracted cells.

[0171] Sample data: 4A and 4B show images of a subsection of a microcapillary array using bright field imaging (FIG. 4A) and fluorescent imaging (FIG. 4B) to identify microcapillaries with expressing and non-expressing cells.

[0172] Example 4. Growth of cultured human cells in microcapillary arrays Figures 5A-5G show the growth of K562 cells (a human immortalized myeloid leukemia cell line) in growth medium over a 6-day period in an array of microcapillaries. Brightfield images of the same portion of the array were taken every 24 h. Figure 5A: day 0, Figure 5B: day 1, Figure 5C: day 2, Figure 5D: day 3, Figure 5E: day 4, Figure 5F: day 5, and Figure 5G: day 6. A scale bar of 40 μm is indicated for each image.

[0173] Example 5. Hybridoma screening for mammalian reporter cells To identify antibody variants that activate specific signaling pathways, hybridomas secreting different antibody variants were added to a microcapillary array along with reporter cells, for example, available from Qiagen (see http: / / www.sabiosciences.com / reporter_assay_product / HTML / CCS-013L.html). When the protein variant binds to the reporter cells and activates a signaling pathway, the reporter cells express a fluorescent protein, and the signal fluorescence of the activated cells is observed in the microcapillaries containing the desired protein variant and used to isolate the contents of those microcapillaries.

[0174] Example 6. Sample Data for Multiple Target Binding Research purpose: Hybridomas secreting antibodies that specifically bind to the target protein but not to proteins of similar structure are identified. See, for example, Figure 9. This method allows for the screening of antibody libraries and does so on an ongoing basis.

[0175] material: Hybridoma Library

[0176] The target protein is displayed on the cancer cell type. See, for example, FIG.

[0177] The target protein analogue is immobilized on the beads, see for example Figure 9. protocol: 1. Cells displaying target protein A on their surface were cultured. 2. Protein Dynabeads Biotin Binder was labeled with target protein B according to the manufacture's instructions. 3. A rat hybridoma library was cultured. 4. The cells, beads and hybridomas were diluted so that there was an average of 1 hybridoma, approximately 2 cells of target protein A cells, and approximately 10 beads coated with target protein B per microcapillary. 5. Anti-rat secondary antibody (reporter element) was added to the prepared cell sample. 6. Samples were loaded onto the array. 7. Incubate for 1 hour before imaging. 8. Cells that bind target protein A but not target protein B and beads were collected.

[0178] Sample results: Microcapillaries that had appropriately stained cells but no stained beads were identified. The presence of stained cells and the absence of stained beads in the microcapillary indicated the presence of an antibody that binds to the target protein but not to the target protein analogue.

[0179] In some embodiments, the assay tested in this example can alternatively be adapted to screen for antibodies that bind to both mouse and human (or other animal combination) variants of a target protein, i.e., to discover "cross-reactive" antibodies. For example, the presence of stained cells and the presence of stained beads in the microcapillary indicates the presence of an antibody that binds to the "target protein" (e.g., mouse target) and also binds to a "target protein analog" (e.g., human target) to identify an antibody that binds to both mouse and human targets. For example, the presence of stained cells and the presence of stained beads in the microcapillary indicates the presence of an antibody that binds to the "target protein" (e.g., cynomolgus target) and also binds to a "target protein analog" (e.g., human target) to identify an antibody that binds to both cynomolgus and human targets.

[0180] Example 7. Titration of reporter elements for optimal signal output A frequently used reporter element is a fluorescently labeled secondary antibody. In this assay format, a secondary antibody is added at the start of the assay and, over time, this antibody binds to the secreted antibody (mutant protein) that is bound to the target protein.

[0181] An important consideration was the amount of secondary antibody used. Too much secondary antibody will result in too high background noise. Using too little secondary antibody will result in too low a signal. In this experiment, beads were labeled with a primary antibody and then titrated with various levels of secondary antibody to determine the optimal signal to noise ratio.

[0182] The reporter element used was a donkey anti-goat IgG secondary antibody labeled with Alexa Fluor633.

[0183] Manufacturer recommended usage range: 1:200 to 1:2000 dilution range.

[0184] The dilution series tested was 1:100, 1:200, 1:500, 1:1000, 1:2000, 1:5000. Images of beads from the experiment are shown in FIG.

[0185] All patents, patent publications, and other published references mentioned herein are incorporated by reference in their entirety herein, as if each was individually and specifically incorporated by reference.

[0186] Although specific examples have been provided, the above description is illustrative and not restrictive. Any one or more of the features of the above-described embodiments may be combined in any manner with one or more features of any other embodiment of the present invention. Furthermore, upon review of this specification, many variations of the present invention will become apparent to those skilled in the art. Thus, the scope of the present invention should be determined by reference to the appended claims, along with their full range of equivalents.

[0187] The above examples are provided to give those skilled in the art a complete disclosure and description of how to make and use the embodiments of the compositions, systems, and methods of the present invention, and are not intended to limit the scope of what the inventors regard as their invention. Modifications of the above modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the appended claims. All patents and publications mentioned in this specification are indicative of the level of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference was individually incorporated by reference in its entirety.

[0188] All heading and section designations are used for clarity and reference purposes only and should not be considered limiting in any way For example, one of ordinary skill in the art will recognize the utility of combining various aspects from different headings and sections as appropriate in accordance with the spirit and scope of the invention described herein.

[0189] All references cited in this specification are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.

[0190] It will be apparent to those skilled in the art that many modifications and variations of this application can be made without departing from the spirit and scope of the present application. The specific embodiments and examples described herein are offered by way of example only and should be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims

1. 1. A method for screening a population of mutant proteins comprising the steps of: providing a microcapillary array comprising a plurality of microcapillaries, each microcapillary comprising a mutant protein, an immobilized target molecule, and a reporter element, wherein the mutant protein associates with the immobilized target molecule with a particular affinity; and measuring a signal from at least one reporter element indicating association of at least one mutant protein with at least one immobilized target molecule to identify at least one microcapillary of interest.

2. The method of claim 1 , wherein the mutant protein is expressed by an expression system.

3. The method of claim 2 , wherein the expression system is a cell-free expression system.

4. The method of claim 2 , wherein the expression system is a cellular expression system.

5. 5. The method of claim 4, wherein the cellular expression system is animal-, fungal-, bacterial-, insect-, or plant-based.

6. The method of claim 5 , wherein the cellular expression system is a yeast system.

7. The method of claim 1 , wherein the mutant protein is a soluble protein.

8. The method of claim 1 , wherein the target molecule is a target protein or polypeptide, a target nucleic acid, a target carbohydrate, or a combination of each.

9. The method of claim 1 , wherein the target molecule is immobilized on a surface.

10. The method of claim 9 , wherein the surface is a surface of a cell.

11. The method of claim 9 , wherein the target molecule is a naturally occurring protein.

12. The method of claim 9 , wherein the surface is a surface of a bead.

13. The method of claim 9 , wherein the surface is a surface of a microcapillary wall.

14. 10. The method of claim 9, wherein the surface is a surface configured to settle within the microcapillary by gravitational settling.

15. The method of claim 1 , wherein the reporter element is a labeled antibody or other binding molecule.

16. The method of claim 15, wherein the labeled antibody or other binding molecule is a fluorescently labeled antibody or other binding molecule.

17. The method of claim 15, wherein the labeled antibody is a primary antibody or a secondary antibody.

18. The method of claim 15, wherein the labeled antibody or other binding molecule is an enzyme-linked antibody or other binding molecule.

19. The method of claim 1 , wherein the reporter element is activated within a cell and the target molecule is immobilized on the surface of the cell.

20. 20. The method of claim 19, wherein the reporter element comprises a green fluorescent protein or a mutant.

21. The method of claim 1 , wherein the signal is a fluorescent signal, an absorbance signal, a bright field signal, or a dark field signal.

22. The method of claim 1, wherein each microcapillary in the microcapillary array contains 0 to 5 mutant proteins from the population of mutant proteins.

23. 10. The method of claim 1, wherein the microcapillary array comprises at least 100,000, at least 300,000, at least 1,000,000, at least 3,000,000, or at least 10,000,000 microcapillaries.

24. 10. The method of claim 1, wherein each microcapillary further comprises an agent for improving the viability of the cell expression system.

25. 25. The method of claim 24, wherein the agent is methylcellulose, dextran puronic F-68, polyethylene glycol, or polyvinyl alcohol.

26. 25. The method of claim 24, wherein the agent is a growth medium.

27. The method of claim 1 , wherein the signal is measured by a photodetector.

28. The method of claim 1 , wherein the signal is measured by microscopy.

29. 10. The method of claim 1, further comprising the step of isolating the contents of the microcapillary of interest.

30. 30. The method of claim 29, wherein the contents of the microcapillary of interest are isolated by pulsing the microcapillary of interest with a laser.

31. 31. The method of claim 30, wherein the laser is a diode-pumped Q-switched laser.

32. 31. The method of claim 30, wherein the laser is directed at a water-glass interface between the microcapillary wall and a sample contained in the microcapillary.

33. 30. The method of claim 29, wherein the contents of the microcapillary of interest are isolated using a two-stage sample collection element.

34. The method of claim 1 , wherein the microcapillary does not contain microparticles, magnetic microparticles, magnetic beads, or electromagnetic radiation absorbing materials capable of suppressing the transmission of electromagnetic radiation.

35. 1. A system for screening a population of mutant proteins, comprising: A system comprising an array comprising a plurality of microcapillaries, each microcapillary comprising a mutant protein, an immobilized target molecule, and a reporter element, wherein the mutant protein associates with the immobilized target molecule with a particular affinity.

36. The screening system of claim 35, wherein the mutant protein is expressed by an expression system.

37. The screening system of claim 36 , wherein the expression system is a cell-free expression system.

38. The screening system of claim 36 , wherein the expression system is a cellular expression system.

39. 39. The screening system of claim 38, wherein the cellular expression system is animal-, fungal-, bacterial-, insect-, or plant-based.

40. The screening system of claim 39 , wherein the cell expression system is a yeast system.

41. The screening system of claim 35, wherein the mutant protein is a soluble protein.

42. The screening system of claim 35, wherein the target molecule is a target protein or polypeptide, a target nucleic acid, a target carbohydrate, or a combination of each.

43. The screening system of claim 35 , wherein the target molecule is immobilized on a surface.

44. The screening system of claim 43, wherein the surface is a surface of a cell.

45. The screening system of claim 44, wherein the target molecule is a natural protein.

46. 44. The screening system of claim 43, wherein the surface is a surface of a bead.

47. 44. The screening system of claim 43, wherein the surface is a surface of a microcapillary wall.

48. 44. The screening system of claim 43, wherein the surface is configured to settle within the microcapillary by gravitational settling.

49. The screening system of claim 35, wherein the reporter element is a labeled antibody or other binding molecule.

50. The screening system of claim 49, wherein the labeled antibody or other binding molecule is a fluorescently labeled antibody or other binding molecule.

51. The screening system of claim 49 , wherein the labeled antibody is a primary antibody or a secondary antibody.

52. 50. The screening system of claim 49, wherein the labeled antibody or other binding molecule is an enzyme-linked antibody or other binding molecule.

53. The screening system of claim 35, wherein the reporter element is activated within a cell and the target molecule is immobilized on the surface of the cell.

54. The screening system of claim 53, wherein the reporter element comprises a green fluorescent protein or a mutant thereof.

55. The screening system of claim 35 , wherein the signal is a fluorescent signal, an absorbance signal, a bright field signal, or a dark field signal.

56. The screening system of claim 35, wherein each microcapillary in the microcapillary array contains 0 to 5 mutant proteins from the population of mutant proteins.

57. 36. The screening system of claim 35, wherein the microcapillary array comprises at least 100,000, at least 300,000, at least 1,000,000, at least 3,000,000, or at least 10,000,000 microcapillaries.

58. 36. The screening system of claim 35, wherein each microcapillary further comprises an agent for improving the viability of the cell expression system.

59. 59. The screening system of claim 58, wherein the agent is methylcellulose, dextran puronic F-68, polyethylene glycol, or polyvinyl alcohol.

60. 59. The screening system of claim 58, wherein the agent is a growth medium.

61. 36. The screening system of claim 35, wherein the system further comprises a light source and a detector.

62. The screening system of claim 35 , wherein the system further comprises a microscope.

63. 36. The screening system of claim 35, wherein the system further comprises an extraction device.

64. 64. The screening system of claim 63, wherein the extraction device comprises a diode-pumped Q-switched laser.

65. 36. The screening system of claim 35, wherein the system further comprises a two-stage sample collection element.

66. 36. The screening system of claim 35, wherein the microcapillaries do not contain microparticles, magnetic microparticles, magnetic beads, or electromagnetic radiation absorbing materials capable of suppressing the transmission of electromagnetic radiation.